A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. Counterpoint.
about
Diabetes mellitus and renal failure: Prevention and managementDiabetic kidney disease: a report from an ADA Consensus ConferenceUpdates on the management of diabetes in dialysis patientsDiabetes Care: “state of the union”Management of diabetes mellitus in patients with chronic kidney diseaseDietary restrictions in dialysis patients: is there anything left to eat?Management of Hyperglycemia in Diabetic Kidney Disease.Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients.Should Restrictions Be Relaxed for Metformin Use in Chronic Kidney Disease? No, We Should Never Again Compromise Safety!Management of hyperglycemia in hospitalized patients with renal insufficiency or steroid-induced diabetes.Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population?Hemoglobin a1c in the ESRD population: status report.Antidiabetic Therapy in End-Stage Renal Disease.Measurement of Hba(1C) in patients with chronic renal failure.Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease.Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease.Association of Glycemic Status During Progression of Chronic Kidney Disease With Early Dialysis Mortality in Patients With Diabetes.Glycated albumin, not hemoglobin A1c, predicts cardiovascular hospitalization and length of stay in diabetic patients on dialysis.Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.The Glycemic Indices in Dialysis Evaluation (GIDE) study: Comparative measures of glycemic control in diabetic dialysis patients.Glycated albumin and continuous glucose monitoring to replace glycated haemoglobin in patients with diabetes treated with haemodialysis.Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).Glycemic Control Assessment in the Dialysis Patient: Is Glycated Albumin the Answer?
P2860
Q26768488-B47DBE58-F84E-426A-95E4-41C162DC5808Q27012546-75370FED-484A-4196-8A78-A09181BCA21DQ27024782-91418876-3401-4984-A4AD-BC8FDCE2C958Q28710273-1B324B90-E4B7-4B1F-A2A1-A5195ED04CFDQ33792375-ADDA8A7E-7EAE-4C21-A1A8-EC55AB9E2F58Q35272314-6CEF5FFE-5D94-44F0-BFCD-F4C6FC542A39Q35953856-B17C8187-0B5F-4292-AF55-C95ED6D5734EQ36868213-1906D370-902A-4C9A-B735-AD8EA9BBC0E1Q37025558-054AA80C-BE6F-4B4F-A6C7-7EA8009B623AQ38054558-AA389271-2F1D-475C-8A10-EF4451E6FF6AQ38182542-66DFBF0C-F941-4938-8EEF-043519553386Q38231450-2C62B33E-2CFD-48C2-A410-8263BD9FAA39Q38433245-6E3F3C56-E6A6-46E0-BCF1-0583D3E6A9D0Q38541529-B49ADF49-0CA9-4098-BAF4-23E60978D2F9Q38688345-AF8CC819-DAF6-42A5-AF8C-A8E29A7704DBQ38878430-A0B64B6A-6816-4FFE-B00F-72FF76909413Q40168373-4E8DDCDD-EE8E-4610-AE9C-615B3BBBE08CQ42286738-06D7B901-288D-40EC-9832-0933A7CFAE8BQ45072634-67C19030-BE6C-4A91-B38B-E3B3BBFA1EA1Q46428227-EEFD9DD8-B2F3-43E6-AA82-C9B5B4A6ABBBQ47874196-9F1C6C66-31DE-46B4-8E56-3DDBA79420E3Q48118116-CB76BEA9-DE88-4D10-9623-37614C47CDDDQ49593330-0E3D5ECC-DBE0-46B8-B876-AC9B32848F08
P2860
A critical evaluation of glycated protein parameters in advanced nephropathy: a matter of life or death: A1C remains the gold standard outcome predictor in diabetic dialysis patients. Counterpoint.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A critical evaluation of glyca ...... alysis patients. Counterpoint.
@ast
A critical evaluation of glyca ...... alysis patients. Counterpoint.
@en
type
label
A critical evaluation of glyca ...... alysis patients. Counterpoint.
@ast
A critical evaluation of glyca ...... alysis patients. Counterpoint.
@en
prefLabel
A critical evaluation of glyca ...... alysis patients. Counterpoint.
@ast
A critical evaluation of glyca ...... alysis patients. Counterpoint.
@en
P2860
P356
P1433
P1476
A critical evaluation of glyca ...... alysis patients. Counterpoint.
@en
P2860
P304
P356
10.2337/DC12-0483
P407
P577
2012-07-01T00:00:00Z